Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
Translational Psychiatry August 29, 2025 Anton L. V. Avanceña, Linh N. Vuong, James G. Kahn et al. 8 citations
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individual-level, probabilistic simulation model that portrays representative US adults with TRD who...
DOI: 10.1038/s41398-025-03556-4 (opens in new tab)
Full text (opens in new tab)
Treatment-resistant depression
Major depressive disorder
Quality-adjusted life year
Cost effectiveness
+4